StockWatch
·
HomeLiveReports

Star Health and Allied Insurance Company Ltd Q1 FY27 Results

STARHEALTHQ1 FY27 Results
Filing
STAR HEALTH · Q1 FY27 · THE VERDICT

The ₹95 Crore Underwriting Win That Cost Market Share

Underwriting profit surged ₹95 crore to ₹111 crore in a fourth consecutive quarter of improvement. But market share fell to 29%, insurance revenue lagged GWP by 5.6 percentage points, and normalised profit (+44%) tells a very different story than reported profit (+25%). This is disciplined execution—just not broad-based growth.

16 Aug 2026 · 6 min read
Reported PAT

₹550 Cr

+25% YoY

Normalised PAT

₹386 Cr

8% investment yield; +44% YoY

Underwriting Result

₹111 Cr

vs ₹16 Cr Q1 FY26; ₹95 Cr swing

Market Share

29%

Down from 31% Q1 FY26

The headline profit number jumps off the page—₹550 crore, up a quarter. But when you strip out mark-to-market investment gains (normalised at 8% yield), the organic profit is ₹386 crore, which is a much healthier +44% year-on-year. That gap is the first clue: this is a quarter where underwriting execution worked, but investment volatility and long-term policy recognition mix have muddied the optics. Strip those away, and what you find is genuine.

The underwriting turnaround is real—the fourth consecutive quarter holds up

Star Health swung ₹95 crore from an underwriting loss of ₹16 crore (Q1 FY26) to a profit of ₹111 crore. This is the result of four quarters of stacked improvement: repricing, portfolio selection, claims management, and telemedicine scaled to handle fever and infectious disease claims. The loss ratio (retail book) sits in the 67.5–68% range, down from higher levels 18 months ago. Combined with a 1.7-point improvement in the combined insurance service ratio (CISR, now 97%), the operational momentum is credible.

Fresh business is the tailwind: 94% new-to-insurance, a best-in-class figure (up from 90% Q1 FY26). Gross written premium (GWP) on fresh retail health grew 37% year-on-year to ₹730 crore (1/N basis). The digital D2C channel alone grew 142% year-on-year and is now 98% new-to-insurance—the fastest-growing profitable channel. Agency productivity rose 19% year-on-year, and the renewal ratio improved to 102%, a signal that the back-book is stable.

But the growth narrative is compromised—and management is transparent about why

Market share fell to 29% from 31% year-on-year. Management attributes this to a strategic choice: they are prioritising long-term policy mix and disciplined underwriting over market share chase. That's a credible defence, and the data supports it—fresh business is strong, so the share decline is not about losing customers; it's about the mix of how policies are reported (1/N basis vs. N basis for long-term business). But the optics matter: a 2-point retreat is a retreat, and it will weigh on sentiment until the category recovers or Star Health actively rebuilds.

Insurance revenue growth (13.4% year-on-year) lags GWP growth (19%) by 5.6 percentage points. This is a timing issue: ~40% of fresh business is long-term policies, which are earned over 2–3 years, not a quarter. Management guided that insurance revenue will converge to 15–16% growth as the long-term policy mix normalises through the year. This is new guidance (first time quantified on a call), and the logic is sound. But it remains unproven—execution will matter.

₹ Crore
013.8127.6341.4437Fresh GWP growth13.4Insurance revenue growth15.5Expected convergence
Insurance revenue growth (%) lags GWP due to long-term policy earned premium timing. Management expects gradual convergence to 15-16% as the mix normalises.

What changed on this call

  • Insurance revenue guidance clarified to 15-16% (new quantification; prior call did not specify)

  • Reinsurance cost guided lower: 0.5-0.6% for FY27-28 vs. ~0.9% FY26 (voluntary quota share treaty fading)

  • Market share decline explained as strategic, not competitive (but no recovery guidance given; management expects 'clean like-for-like by FY28')

  • Loss ratio improvement reaffirmed—fourth consecutive quarter—but no guidance given (management cited 360-degree approach and declined to quantify by component)

  • Mid-to-high teen ROE target reaffirmed steady-state; glide path evident over last 3-4 quarters

Management's claims vs. what holds up

Four key assertions tested against the numbers

Fourth consecutive quarter of UW profitability improvement

UW result ₹111 Cr vs ₹16 Cr Q1 FY26; CISR improved 1.7 pts to 97%; ₹95 Cr swing credible

Supported

Fresh business 94% new-to-insurance (best-in-class)

94% vs 90% Q1 FY26; fresh GWP +37% YoY

Supported

Disciplined risk selection driving market share decline

Market share fell 31% → 29%; but decline attributed to long-term policy reporting mix, not loss of customers

Overstated (it's timing, not pure discipline)

D2C fastest-growing profitable channel

D2C fresh business +142% YoY; 74% of digital, 98% new-to-insurance

Supported

Telemedicine scaled significantly to manage fever and infectious disease claims

Management noted 'huge scale-up' quarter-to-quarter; no specific adoption rate or prior comparison given

Partial (plausible, unquantified)

The bull-bear ledger

  • Fourth consecutive quarter of underwriting profit improvement is genuine and auditable

  • Fresh business momentum (94% new-to-insurance, +37% GWP growth) validates digital and direct channels

  • Proprietary distribution scale (8.5 lakh agents, 90% of retail business, 16M app downloads) is durable moat against regulatory commission reform

  • Renewal ratio 102%, claim settlement ratio 91%, NPS +12 pts YoY—retention and loyalty building

  • Long-term policy mix (~40% of fresh) depresses insurance revenue growth to 13.4% vs. GWP 19%; convergence to 15-16% unproven

  • Market share fell to 29% from 31% YoY; management characterises as strategic but provides no recovery timeline

  • Loss ratio improvement (100 bps implied) may be peaking; analyst skepticism on magnitude vs. fresh/digital tailwinds real

  • Reported PAT inflated by mark-to-market gains; normalised PAT +44% is the organic number

  • Q2 seasonal vector-borne disease spike expected; telemedicine mitigation unquantified

  • Regulatory uncertainty on commission and claims reforms; Star Health 90% proprietary distribution is hedge, but timeline/impact unknown

Risks, ranked by how much they should concern a holder

Five critical risks ordered by severity and holder impact

Loss ratio improvement trajectory may be peaking or stalling

High

100 bps YoY improvement is real, but analyst skepticism ('this could have been much better') reflects concern that back-book deterioration is offsetting new-book gains. If loss ratio plateaus at ~68%, UW margin expansion stalls and ROE glide-path slows.

Insurance revenue growth lag unresolved; long-term policy mix timing unproven

High

13.4% insurance revenue growth vs. 19% GWP is a 5.6 pt gap. Convergence to 15-16% depends on earned premium recognition over 2-3 years. If market slows or fresh growth moderates post-GST waiver in H2, absolute revenue could dip below guidance.

Market share compression (31% → 29%) with no recovery timeline disclosed

Medium

Star Health is largest retail health insurer, but 2-point retreat signals either competitive loss or self-imposed margin focus. If competitors gain share while Star pursues profitability, market leadership erodes; management expects 'clean like-for-like by FY28' but that is vague.

Q2 seasonal vector-borne disease spike; telemedicine mitigation unquantified

Medium

Q2 (Jul-Sep) typically sees dengue, malaria spikes; loss ratios historically higher. Management noted telemedicine scale-up but provided no adoption rate or claim settlement impact. If outbreak exceeds expected or TM effectiveness is lower, claims surge and margin compresses.

Regulatory commission and claims reform uncertainty; timeline and impact opaque

Medium

IRDAI is expected to reform commissions and claims processes. Star Health 90% proprietary distribution is a hedge, but reforms could cap acquisition costs anyway or require structural shifts. Management deferred all regulatory commentary ('will comment after rules out')—prudent, but limits forward clarity.

Normalised PAT methodology (8% investment yield normalisation) masks volatility; MTM swings material

Low

Reported PAT ₹550 Cr includes investment mark-to-market gains. Normalised PAT ₹386 Cr (+44%) is the organic number, but normalisation assumption (8% yield) is backward-looking. If yield environment changes or rate volatility persists, earnings swings will obscure operational trends.

How the street is positioned—and what it says about the print

Price action: The result was announced on 29 July 2026 (pre-result close ₹598.85). The day-1 pop was +1.93%, driven on the headline profit jump. But by day 3 the move had faded to -1.04%, and by day 5 it was -1.8% net. As of 16 August, the stock trades at ₹585.15—a net decline from the announcement print, and 6.36% below its all-time high of ₹624.9. The stock is above its 50-day SMA (₹575.3) and 200-day SMA (₹502.67), so it remains in a medium-term uptrend. But the fade from the result pop signals that the street sees the profit number as inflated by MTM gains and the forward growth trajectory as constrained by revenue lag and market share pressure.

Ownership momentum: FII ownership rose 0.99 percentage points to 16.04% quarter-on-quarter (from 15.05% in Q4 FY26), while DII trimmed 0.9 percentage points to 19.41%. The promoter stake held steady at 58.01% (up marginally 0.03 pp). This is a modest rotation: foreigners are adding into strength, but domestic institutions are lightening. It suggests a bifurcated view—international money betting on the underwriting turnaround, domestic money questioning whether that alone justifies current valuations.

Valuation context: At ₹585.15, Star Health sits 40.5% above its 52-week low (₹416.55) and 6.36% below its all-time high (₹624.9). The stock has recovered sharply off its February-March 2025 lows, but has given back the post-earnings euphoria. For a company delivering ₹111 crore in underwriting profit (up from ₹16 crore) and normalised PAT growth of 44%, the lack of a sustained pop is telling—the market is pricing in that growth will slow as reinsurance fades, market share headwinds persist, and regulatory uncertainty builds.

The debate—and the honest read

What to watch next—the 2–3 things that resolve the debate

Catalysts for the next 6–9 months

  • 1 · Q2 FY27 result (Oct-Nov 2026)

    Vector-borne disease spike expected; telemedicine effectiveness is the variable. If loss ratio holds or improves despite seasonal headwinds, the 360-degree management approach is validated. If loss ratio spikes >70%, the 100 bps improvement trajectory stalls.

  • 2 · Insurance revenue growth trajectory through H2 FY27 (Jan-Mar 2027)

    Will insurance revenue growth accelerate toward 15-16% as long-term policies are recognized and GST waiver moderation base effects unwind? Or will it remain stuck at 13-14%, implying management's convergence guidance is too optimistic?

  • 3 · Market share stabilization signal (H2 FY27 onward)

    Management expects 'clean like-for-like by FY28.' By Q3-Q4 FY27, will the company show evidence of market share reacceleration (through pricing actions, agency expansion, digital mix shift), or will the 29% level persist as a new baseline?

  • 4 · Regulatory guidance on commission and claims reforms (ongoing)

    IRDAI proposals expected in H2 FY27. Will the rules cap commissions in a way that pressures Star Health's 90% proprietary distribution model, or will the rules be narrower than feared?

The single number to track from here

Insurance revenue growth quarter-on-quarter through FY27. Q1 came in at 13.4%; watch for acceleration toward 15-16% as long-term policies earned and GST base effects normalize. If it stays in the 13-14% band through H2, the convergence guidance breaks and revenue growth becomes a structural headwind to ROE progression.

Star Health has proven it can tighten underwriting and win profitability. The ₹95 crore swing in underwriting profit, the fourth consecutive quarter of improvement, the 102% renewal ratio, and the 94% new-to-insurance penetration all testify to that. But profits won on a shrinking market share and a revenue growth lag are not the same as profits won on momentum. The company is executing a disciplined, long-term strategy: sacrifice near-term share and revenue growth for durable underwriting discipline and margin. That is honest work. Whether the street rewards it depends on whether insurance revenue growth converges to 15-16% as promised and whether market share stabilizes by FY28. Until then, this is a Hold—credible execution with measured enthusiasm, not a breakout turnaround. The valuation has not recovered to all-time highs for good reason: the story is steady, not a step-change.

Informational and educational content only. Not investment advice.